🇺🇸 FDA

Drug profile · INN

linaclotide

CONSTELLA

approved A06AX04
US status
approved
Patents linked
3
News articles
0

Quick answer

linaclotide (CONSTELLA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN linaclotide
Brand CONSTELLA
Route ORAL
Formulation CAPSULE
ATC code A06AX04

Related patents

Search patents →

  1. US 10702576

    Stable formulations of linaclotide

    Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10675325

    Stable formulations of linaclotide

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8748573

    Formulations comprising linaclotide

    Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is linaclotide?

linaclotide (CONSTELLA) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for linaclotide?

CONSTELLA is a marketed brand name for linaclotide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of linaclotide?

linaclotide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.